Bio-Reference Labs (Nasdaq:BRLI) is an odd diagnostics company. It combines a somewhat sleepy conventional diagnostics business centered on the Northeast (New York City, in particular) with a nationwide esoteric testing business. The company has had a less-than-spectacular record of cash flow generation and cash conversion, but it has improved significantly in recent times. While its smaller scale and fierce competition from Quest (NYSE:DGX) and LabCorp (NYSE:LH) are risk factors, growth in the esoteric testing business could make this a name worth following.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Diagnostics a Good Place to Be
As a testing services provider, Bio-Reference Labs is in a pretty attractive business. Unlike much of the healthcare sector, these companies don't live in any particular fear of government reimbursement. While Medicare and Medicaid are major components of the overall U.S. healthcare industry, Medicare and Medicaid are only about 20% of the business for Quest, LabCorp, and Bio-Reference. While that does not mean they're immune to reimbursement pressures, it does give them a much lower exposure than companies like Lincare (Nasdaq:LNCR) or even a larger diversified drug and device company like Johnson & Johnson (NYSE:JNJ).

Another benefit to the diagnostics service industry is that it exploits the R&D competition of others. While there is an arms race to develop, posses, and market exclusive tests, this sector benefits from the competition between companies like Abbott (NYSE:ABT), Bio-Rad (NYSE:BIO), Becton Dickinson (NYSE:BDX) and Luminex (Nasdaq:LMNX). These companies are all competing to develop systems and tests that offer economic advantages to companies like Bio-References in terms of greater throughput, improved accuracy and less hands-on time.

SEE: Companies Playing Catch-Up With The Competition

Combining Regional and National
Bio-Reference has a somewhat different model. The company is relatively large in terms of regional routine test providers, and holds a strong share of the New York market. It's a smaller player on the national scope, though, but is seeing strong growth from its molecular diagnostics capabilities and units like GenPath and GeneDx. A fair bit of the 19% revenue growth seen in the last quarter, for instance, was due to the growth of this esoteric testing business.

The question is whether Bio-Reference can compete on a nationwide basis for the long-term. LabCorp and Quest have substantial resources, as to other companies like PerkinElmer (NYSE:PKI) and General Electric (NYSE:GE). While tie-ups with small companies such as InCellDx will help give it access to proprietary tests, this is a small company in an arms race where R&D and marketing dollars can make a real difference.

SEE: Crazy Research The U.S. Government Is Funding

Time to Think, and Act, Like a Bigger Company
In many respects, Bio-Reference still behaves like a smaller company and that's not necessarily to the advantage of shareholders. Management seems disinterested in the possibility that it could be an acquisition target, and the company's decision to stick with a smaller auditor has seemingly helped fuel accusations of weak financial controls. Likewise, the company has not historically been very efficient with cash collections and the company's days sales outstanding has been a lot higher than the industry norm in years past.

Some of this is already improving; the company's cash collection cycle has been getting quite a bit better lately. Moreover, I don't think changing auditors just to impress people with a better-known name makes much economic sense. Nevertheless, the company's past decisions and past volatility in financial results opens itself up to trouble and a failure to adopt "big company practices" may well interfere with future growth plans.

SEE: The Evolution Of Enterprise Risk Management

The Bottom Line
Buying Bio-Reference really comes down to an investor's confidence in the growth prospects for the national esoteric testing business. The opportunity is absolutely there; molecular diagnostics is both a double-digit growth market and one that can be measured in the multiple billions of dollars. Moreover, considering the opportunity in markets like cancer, immunology and endocrinology alone, there's plenty of runway here to support many years of double-digit growth at BRLI.

On the other hand, investors have to remember and realize that companies like LabCorp and Quest are already big players in the esoteric market, and that this is a market where strength frequently builds upon strength. This is also a stock already near its 52-week high.

All in all, then, this is a somewhat typical high-risk/high-reward opportunity. As part of a diversified portfolio, Bio-Reference could be a good addition, but I'd wait for a pullback before buying shares.

At the time of writing, Stephen D. Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: iShares Morningstar Small-Cap Value

    Find out about the Shares Morningstar Small-Cap Value ETF, and learn detailed information about this exchange-traded fund that focuses on small-cap equities.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  9. Mutual Funds & ETFs

    ETF Analysis: WisdomTree SmallCap Earnings

    Discover the WisdomTree Small Cap Earnings ETF, a fund with a special focus on small-cap and micro-cap stocks with positive earnings.
  10. Mutual Funds & ETFs

    ETF Analysis: iShares US Regional Banks

    Obtain information and analysis of the iShares US Regional Banks ETF for investors seeking particular exposure to regional bank stocks.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Profit Margin

    A category of ratios measuring profitability calculated as net ...
  3. Quarter - Q1, Q2, Q3, Q4

    A three-month period on a financial calendar that acts as a basis ...
  4. Debt Ratio

    A financial ratio that measures the extent of a company’s or ...
  5. Price-Earnings Ratio - P/E Ratio

    The Price-to-Earnings Ratio or P/E ratio is a ratio for valuing ...
  6. Net Present Value - NPV

    The difference between the present values of cash inflows and ...
RELATED FAQS
  1. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. When does the fixed charge coverage ratio suggest that a company should stop borrowing ...

    Since the fixed charge coverage ratio indicates the number of times a company is capable of making its fixed charge payments ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. What is the difference between the return on total assets and an interest rate?

    Return on total assets (ROTA) represents one of the profitability metrics. It is calculated by taking a company's earnings ... Read Full Answer >>
  6. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!